SBIR-STTR Award

EyeStar-BIO: Software for Enhancing Digital Binocular Indirect Ophthalmoscopy Examinations
Award last edited on: 2/14/2024

Sponsored Program
SBIR
Awarding Agency
NIH : NEI
Total Award Amount
$302,102
Award Phase
1
Solicitation Topic Code
867
Principal Investigator
Jeffrey Wigdahl

Company Information

VisionQuest Biomedical LLC (AKA: VisionQuest Inc)

2501 Yale Boulevard SE Suite 301
Albuquerque, NM 87106
   (505) 508-1994
   info@visionquest-bio.com
   www.visionquest-bio.com
Location: Single
Congr. District: 01
County: Bernalillo

Phase I

Contract Number: 1R43EY033569-01
Start Date: 6/1/2022    Completed: 11/30/2023
Phase I year
2022
Phase I Amount
$247,627
The goal of the proposed project is to develop EyeStar-BIO, a suite of software tools designed to enhance digital binocular indirect ophthalmoscopy examinations (BIO), one of the most common forms of examination of the retina. Using BIO, an ophthalmologist can determine the presence of multiple retinal diseases such as diabetic retinopathy, macular degeneration, and retinopathy of prematurity, among others. The traditional BIO exam does not produce any visual documentation. EyeStar-BIO will feature innovative features that are not currently offered as part of digital BIO exams: (1) automatic image quality assessment, (2) automatic stitching to create a wide-field view of the retina, (3) longitudinal analysis, and (4) AI-based disease detection. This project has an $800M market potential as BIO examinations remain one of the most common procedures for ophthalmologists. The goals of this Phase I project will be accomplished via three specific aims. Aim 1: implement software for automatic image quality assessment of digital BIO video frames. Aim 2: develop image stitching methods to generate a wide field view of the retina using the best quality frames in the video. Aim 3: generate images to track differences in time due to disease progression or regression. The EyeStar-BIO software will be licensed to manufacturers of digital BIO headsets. Future developments will include real time implementations of EyeStar-BIO and the ability to diagnose retinal disease using artificial intelligence.

Public Health Relevance Statement:
Narrative The objective of this project is to develop the EyeStar-BIO software to revolutionize the way binocular indirect ophthalmoscopy (BIO) examinations are performed. EyeStar-BIO will provide tools for better diagnosis, documentation, and consultation of retinal exams. These features will lead to better diagnostic tools for retinal diseases.

Project Terms:
Artificial Intelligence; AI system; Computer Reasoning; Machine Intelligence; Classification; Systematics; Consultations; Diabetic Retinopathy; Diagnosis; Disease; Disorder; Eye; Eyeball; Future; Goals; Grant; Joints; Macular degeneration; Macular degenerative disease; Malaria; Paludism; Plasmodium Infections; Methods; Ophthalmoscopy; Optometrist; Paper; Patents; Legal patent; Pathology; Patients; Records; Retina; Retinal Disorder; retina disease; retina disorder; retinopathy; Retinal Diseases; Retrolental Fibroplasia; premature retinopathy; Retinopathy of Prematurity; Software; Computer software; Computer Software Tools; software toolkit; Software Tools; Testing; Time; United States; Video Recording; Videorecording; video recording system; Work; Generations; Measures; Price; pricing; Specialist; Caring; base; image processing; Ophthalmoscopes; Funduscopes; improved; Procedures; Image Analysis; Image Analyses; image evaluation; image interpretation; Area; Clinical; Phase; Ensure; Lesion; Visual; Licensing; Disease Progression; Ophthalmologist; Letters; tool; Diagnostic; Techniques; experience; success; skills; Agreement; Disease regression; Devices; develop software; developing computer software; software development; Documentation; Manufacturer Name; Manufacturer; Cell Phone; Cellular Telephone; iPhone; smart phone; smartphone; Cellular Phone; Detection; Development; developmental; Image; imaging; cost; time use; digital; image registration; design; designing; innovation; innovate; innovative; lens; lenses; clinical care; longitudinal analysis; screening; retinal imaging; retina imaging; diagnostic tool

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
$54,475